| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Obesity: preventing and managing the global epidemic. Report of a WHO consultation.
|
World Health Organ Tech Rep Ser
|
2000
|
70.59
|
|
2
|
Obesity is associated with macrophage accumulation in adipose tissue.
|
J Clin Invest
|
2003
|
41.22
|
|
3
|
Interleukin-10 and the interleukin-10 receptor.
|
Annu Rev Immunol
|
2001
|
25.63
|
|
4
|
Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance.
|
Science
|
1993
|
25.54
|
|
5
|
The hormone resistin links obesity to diabetes.
|
Nature
|
2001
|
15.49
|
|
6
|
Inflammatory mechanisms in obesity.
|
Annu Rev Immunol
|
2011
|
9.83
|
|
7
|
Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group.
|
N Engl J Med
|
1995
|
6.51
|
|
8
|
Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes.
|
J Med Chem
|
2008
|
5.15
|
|
9
|
Glucose transporters and insulin action--implications for insulin resistance and diabetes mellitus.
|
N Engl J Med
|
1999
|
5.05
|
|
10
|
Mechanism by which metformin reduces glucose production in type 2 diabetes.
|
Diabetes
|
2000
|
4.80
|
|
11
|
Adipose tissue dysfunction in obesity, diabetes, and vascular diseases.
|
Eur Heart J
|
2008
|
4.74
|
|
12
|
Diabetic Ketoacidosis and Related Events in the Canagliflozin Type 2 Diabetes Clinical Program.
|
Diabetes Care
|
2015
|
4.64
|
|
13
|
Metabolic effects of metformin in non-insulin-dependent diabetes mellitus.
|
N Engl J Med
|
1995
|
4.29
|
|
14
|
Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes.
|
Diabetes Care
|
2008
|
4.20
|
|
15
|
Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium-Glucose Cotransporter 2 Inhibition.
|
Diabetes Care
|
2015
|
3.80
|
|
16
|
Long-term drug treatment for obesity: a systematic and clinical review.
|
JAMA
|
2014
|
3.69
|
|
17
|
Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: a 24-week, multicenter, randomized, double-blind, placebo-controlled study.
|
Diabetes Care
|
2013
|
3.10
|
|
18
|
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients.
|
J Clin Invest
|
2014
|
3.10
|
|
19
|
Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis.
|
Ann Intern Med
|
2013
|
3.08
|
|
20
|
Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus.
|
Clin Pharmacol Ther
|
2009
|
2.96
|
|
21
|
Interleukin-6 induces cellular insulin resistance in hepatocytes.
|
Diabetes
|
2002
|
2.85
|
|
22
|
Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion.
|
Nat Med
|
2015
|
2.85
|
|
23
|
Glucose transporters (GLUT and SGLT): expanded families of sugar transport proteins.
|
Br J Nutr
|
2003
|
2.62
|
|
24
|
Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin.
|
J Clin Endocrinol Metab
|
2012
|
2.58
|
|
25
|
Euglycemic Diabetic Ketoacidosis: A Predictable, Detectable, and Preventable Safety Concern With SGLT2 Inhibitors.
|
Diabetes Care
|
2015
|
2.27
|
|
26
|
Circulating interleukin 6 levels, blood pressure, and insulin sensitivity in apparently healthy men and women.
|
J Clin Endocrinol Metab
|
2001
|
2.22
|
|
27
|
Effects of dapagliflozin, an SGLT2 inhibitor, on HbA(1c), body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy.
|
Diabetes Care
|
2012
|
2.17
|
|
28
|
Pharmacological management of obesity: an endocrine Society clinical practice guideline.
|
J Clin Endocrinol Metab
|
2015
|
2.05
|
|
29
|
Inflammation, oxidative stress, and obesity.
|
Int J Mol Sci
|
2011
|
2.05
|
|
30
|
Tumor necrosis factor alpha-induced phosphorylation of insulin receptor substrate-1 (IRS-1). Possible mechanism for suppression of insulin-stimulated tyrosine phosphorylation of IRS-1.
|
J Biol Chem
|
1995
|
1.82
|
|
31
|
Inflammation, a link between obesity and cardiovascular disease.
|
Mediators Inflamm
|
2010
|
1.80
|
|
32
|
Association of interleukin-6, C-reactive protein, interleukin-10 and adiponectin plasma concentrations with measures of obesity, insulin sensitivity and glucose metabolism.
|
Exp Clin Endocrinol Diabetes
|
2005
|
1.76
|
|
33
|
Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: a systematic review and meta-analysis.
|
J Am Soc Hypertens
|
2014
|
1.70
|
|
34
|
Role of adiponectin and PBEF/visfatin as regulators of inflammation: involvement in obesity-associated diseases.
|
Clin Sci (Lond)
|
2008
|
1.52
|
|
35
|
Metformin and carbohydrate-modified diet: a novel obesity treatment protocol: preliminary findings from a case series of nondiabetic women with midlife weight gain and hyperinsulinemia.
|
Heart Dis
|
2002
|
1.44
|
|
36
|
[The current state of obesity in Mexico].
|
Rev Med Inst Mex Seguro Soc
|
2013
|
1.44
|
|
37
|
[Prevalence of obesity in Mexican adults 2000-2012].
|
Salud Publica Mex
|
2013
|
1.41
|
|
38
|
Monocyte Chemoattractant Protein 1 (MCP-1) in obesity and diabetes.
|
Cytokine
|
2012
|
1.38
|
|
39
|
Serum retinol-binding protein: a link between obesity, insulin resistance, and type 2 diabetes.
|
Nutr Rev
|
2007
|
1.37
|
|
40
|
Metformin revisited: re-evaluation of its properties and role in the pharmacopoeia of modern antidiabetic agents.
|
Diabetes Obes Metab
|
2005
|
1.33
|
|
41
|
T-1095, an inhibitor of renal Na+-glucose cotransporters, may provide a novel approach to treating diabetes.
|
Diabetes
|
1999
|
1.32
|
|
42
|
Inflammation in obesity is the common link between defects in fatty acid metabolism and insulin resistance.
|
Cell Cycle
|
2007
|
1.30
|
|
43
|
Effects of weight loss after bariatric surgery for morbid obesity on vascular endothelial growth factor-A, adipocytokines, and insulin.
|
J Clin Endocrinol Metab
|
2008
|
1.27
|
|
44
|
Immunity as a link between obesity and insulin resistance.
|
Mol Aspects Med
|
2011
|
1.26
|
|
45
|
Sodium-glucose co-transporter-2 inhibitors: an emerging new class of oral antidiabetic drug.
|
Diabetes Obes Metab
|
2009
|
1.24
|
|
46
|
Weight loss induced by chronic dapagliflozin treatment is attenuated by compensatory hyperphagia in diet-induced obese (DIO) rats.
|
Obesity (Silver Spring)
|
2012
|
1.21
|
|
47
|
The role of the immune system in obesity and insulin resistance.
|
J Obes
|
2013
|
1.08
|
|
48
|
Super obesity and gastric reduction procedures.
|
Gastroenterol Clin North Am
|
1987
|
1.08
|
|
49
|
Metabolic effects of low-dose insulin therapy on glucose metabolism in diabetic ketoacidosis.
|
Diabetes
|
1988
|
1.05
|
|
50
|
Tumour necrosis factor alpha: a key regulator of adipose tissue mass.
|
J Endocrinol
|
2003
|
1.03
|
|
51
|
Repurposing metformin: an old drug with new tricks in its binding pockets.
|
Biochem J
|
2015
|
1.03
|
|
52
|
Long-term treatment with the Na+-glucose cotransporter inhibitor T-1095 causes sustained improvement in hyperglycemia and prevents diabetic neuropathy in Goto-Kakizaki Rats.
|
Life Sci
|
2005
|
1.02
|
|
53
|
Multiple-dose pharmacokinetics and pharmacodynamics of sergliflozin etabonate, a novel inhibitor of glucose reabsorption, in healthy overweight and obese subjects: a randomized double-blind study.
|
J Clin Pharmacol
|
2010
|
0.98
|
|
54
|
Efficacy and safety of dapagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in diabetes mellitus.
|
Cardiovasc Diabetol
|
2015
|
0.98
|
|
55
|
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY POSITION STATEMENT ON THE ASSOCIATION OF SGLT-2 INHIBITORS AND DIABETIC KETOACIDOSIS.
|
Endocr Pract
|
2016
|
0.97
|
|
56
|
Adipose tissue interleukin-18 mRNA and plasma interleukin-18: effect of obesity and exercise.
|
Obesity (Silver Spring)
|
2007
|
0.92
|
|
57
|
Effects of bariatric surgery on adipokine-induced inflammation and insulin resistance.
|
Front Endocrinol (Lausanne)
|
2013
|
0.90
|
|
58
|
Durability of glycaemic efficacy over 2 years with dapagliflozin versus glipizide as add-on therapies in patients whose type 2 diabetes mellitus is inadequately controlled with metformin.
|
Diabetes Obes Metab
|
2014
|
0.89
|
|
59
|
FABP4 dynamics in obesity: discrepancies in adipose tissue and liver expression regarding circulating plasma levels.
|
PLoS One
|
2012
|
0.88
|
|
60
|
Resistin: a new link between obesity and insulin resistance?
|
Clin Endocrinol (Oxf)
|
2001
|
0.86
|
|
61
|
A systematic review and mixed-treatment comparison of dapagliflozin with existing anti-diabetes treatments for those with type 2 diabetes mellitus inadequately controlled by sulfonylurea monotherapy.
|
Diabetol Metab Syndr
|
2014
|
0.83
|
|
62
|
Prospective comparative study in NIDDM patients of metformin and glibenclamide with special reference to lipid profiles.
|
Eur J Clin Pharmacol
|
1991
|
0.82
|
|
63
|
Laparoscopic Roux-en-Y gastric bypass for super/super obesity.
|
Obes Surg
|
1999
|
0.81
|
|
64
|
Type 2 Diabetes, SGLT2 Inhibitors, and Glucose Secretion.
|
N Engl J Med
|
2015
|
0.81
|
|
65
|
Combinational therapy with metformin and sodium-glucose cotransporter inhibitors in management of type 2 diabetes: systematic review and meta-analyses.
|
Diabetes Res Clin Pract
|
2014
|
0.80
|
|
66
|
[Tools to measure treatment adherence].
|
An Med Interna
|
2007
|
0.80
|
|
67
|
Update on long-term efficacy and safety of dapagliflozin in patients with type 2 diabetes mellitus.
|
Ther Adv Endocrinol Metab
|
2015
|
0.78
|
|
68
|
Changes in Levels of Biomarkers Associated with Adipocyte Function and Insulin and Glucagon Kinetics During Treatment with Dapagliflozin Among Obese Type 2 Diabetes Mellitus Patients.
|
Drugs R D
|
2016
|
0.78
|
|
69
|
Effect of gastrointestinal surgical manipulation on metabolic syndrome: a focus on metabolic surgery.
|
Gastroenterol Res Pract
|
2012
|
0.77
|
|
70
|
Protocol for a randomised controlled trial of the effect of dapagliflozin, metformin and exercise on glycaemic variability, body composition and cardiovascular risk in prediabetes (the PRE-D Trial).
|
BMJ Open
|
2017
|
0.75
|
|
71
|
A contemporary approach to body mass regulation mechanisms.
|
Prz Gastroenterol
|
2016
|
0.75
|
|
72
|
New treatments for type 2 diabetes: cardiovascular protection beyond glucose lowering?
|
Heart Lung Circ
|
2014
|
0.75
|
|
73
|
Preoperative weight loss in super-obese patients: study of the rate of weight loss and its effects on surgical morbidity.
|
Clinics (Sao Paulo)
|
2014
|
0.75
|
|
74
|
Effects of SGLT-2 inhibitors on diabetic ketoacidosis: A meta-analysis of randomised controlled trials.
|
Diabetes Res Clin Pract
|
2017
|
0.75
|
|
75
|
[Methodological design of the National Health and Nutrition Survey 2016].
|
Salud Publica Mex
|
2017
|
0.75
|
|
76
|
Glycated Hemoglobin, Body Weight and Blood Pressure in Type 2 Diabetes Patients Initiating Dapagliflozin Treatment in Primary Care: A Retrospective Study.
|
Diabetes Ther
|
2016
|
0.75
|
|
77
|
[Practice clinical guideline. Prevention, diagnosis and treatment of overweight and obesity].
|
Rev Med Inst Mex Seguro Soc
|
2013
|
0.75
|